Ibuprofen and NSAID use in COVID-19 infected patients is not associated with worse outcomes: a prospective cohort sudy

Esba, Laila Carolina Abu, Alqahtani, Rahaf Ali, Thomas, Abin ORCID: https://orcid.org/0000-0002-8283-6762, Shamas, Nour, Alswaidan, Lolowa and Mardawi, Gahdah 2021. Ibuprofen and NSAID use in COVID-19 infected patients is not associated with worse outcomes: a prospective cohort sudy. Infectious Diseases and Therapy 10 , pp. 253-268. 10.1007/s40121-020-00363-w

PDF - Published Version Available under License Creative Commons Attribution Non-commercial. Download (1MB)

Abstract

Introduction Ibuprofen disappeared from the pharmacy shelves during the 2019 coronavirus (COVID-19) pandemic. However, a while later, information circulated that ibuprofen should be avoided as it could worsen COVID-19 symptoms. The aim of our study was to assess the association of acute and chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs) with worse COVID-19 outcomes. Methods We did a prospective cohort study between April 12 and June 1, 2020. Adults consecutively diagnosed with COVID-19 were included. Information on NSAID use was collected through a telephone questionnaire, and patients were followed up for COVID-19 infection outcomes, including death, admission, severity, time to clinical improvement, oxygen requirement and length of stay. Results Acute use of ibuprofen was not associated with a greater risk of mortality relative to non-use (adjusted hazard ratio [HR] 0.632 [95% CI 0.073–5.441; P = 0.6758]). Chronic NSAID use was also not associated with a greater risk of mortality (adjusted HR 0.492 [95% CI 0.178–1.362; P = 0.1721]). Acute ibuprofen use was not associated with a higher risk of admission compared to non-NSAID users (adjusted odds ratio OR 1.271; 95% CI 0.548–2.953). NSAID users did not have a significantly longer time to clinical improvement or length of stay. Conclusion Acute or chronic use of ibuprofen and other NSAIDs was not associated with worse COVID-19 disease outcomes.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine Centre for Trials Research (CNTRR)
Publisher:	Springer
ISSN:	2193-6382
Date of First Compliant Deposit:	18 January 2022
Date of Acceptance:	19 October 2020
Last Modified:	11 May 2023 03:18
URI:	https://orca.cardiff.ac.uk/id/eprint/146600

Citation Data

Cited 42 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item